Rapid sFLC assay shows good clinical concordance when compared with other sFLC assays

In a recent CCLM publication, the authors concluded that Seralite® FLC Serum, a quantitative lateral flow immunoassay, has shown good clinical concordance when compared with other sFLC assays.
 
YORK, U.K. - Dec. 6, 2019 - PRLog -- A study in Clinical Chemistry and Laboratory Medicine (CCLM), authored by Chérina K.A. Fleming et al from Erasmus University Medical Center Rotterdam and Radboud University Medical Center, concluded that Seralite® FLC Serum (Seralite) produced good clinical concordance when compared with other Serum Free Light Chain Assays (sFLC).

The other clinically available sFLCS in question were N-Latex FLC (Siemens), Sebia FLC (Sebia) and Freelite (Binding Site).

The authors highlighted the importance sFLCs and why they are important in the screening of monoclonal gammopathies, prognostic stratification and monitoring response to therapies.

Chérina K.A. Fleming et al, analysed assay performance using 193 anonymous sera samples, with varying FLC-ratios, from patients with Multiple Myeloma (blood cancer) and other related conditions.

The study observed 'good agreements for κFLC, λFLC and FLC ratio between all four assays' and 'clinical concordances were high and ranged from 86% to 92%'.

Facilitating near-patient testing

The study also noted that Seralite's 'advantage' is that it can generate 'rapid FLC results using a portable diagnostic device, facilitating near-patient testing'.

Further details about this publication can be found at https://www.abingdonhealth.com/seralite-flc-serum-shows-good-clinical-concordance/.

Media Contact
***@abingdonhealth.com
01904406082
End
Email:***@abingdonhealth.com Email Verified
Tags:Blood Cancer
Industry:Science
Location:York - North Yorkshire - England
Subject:Reports
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse



Like PRLog?
9K2K1K
Click to Share